id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0117-0008,FDA,FDA-2011-E-0117,"Response Letter from FDA CDER to Boehringer Ingelheim Pharma GmbH & Co. KG, Hogan Lovells US LLP",Other,Answer,2014-12-29T05:00:00Z,2014,12,2014-12-29T05:00:00Z,,2014-12-29T18:32:45Z,,0,0,0900006481996e52